Dr Reddys Laboratories (RDY) Cash & Equivalents Growth (1y) (2010 - 2026)
Powered by 
Analysis
Dr Reddys Laboratories (RDY) Cash & Equivalents Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.60 Bn | 38.94 Bn | 2.15 Bn | 69.13% |
| 2 | Viatris | 19.15 Bn | 18.27 Bn | 1.46 Bn | 56.51% |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | 12.49% |
| 4 | Amneal Pharmaceuticals | 5.49 Bn | 5.36 Bn | 334.51 Mn | 78.40% |
| 5 | Bausch Health Companies | 2.35 Bn | 516.55 Mn | 2.10 Bn | 5.67% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 65.36% |
| 8 | Amphastar Pharmaceuticals | 996.17 Mn | 706.05 Mn | 93.47 Mn | 19.14% |
| 9 | Fennec Pharmaceuticals | 404.39 Mn | 363.15 Mn | 17.15 Mn | 120.52% |
| 10 | RedHill Biopharma | 176.59 Mn | 176.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.49% |
| Mar 31, 2026 | -0.66% |
| Dec 31, 2025 | 35.74% |
| Sep 30, 2025 | -16.04% |
| Jun 30, 2025 | 78.64% |
| Mar 31, 2025 | 97.74% |
| Dec 31, 2024 | 70.56% |
| Sep 30, 2024 | -17.41% |
| Jun 30, 2024 | -33.06% |
| Mar 31, 2024 | 21.73% |
| Dec 31, 2023 | 18.71% |
| Sep 30, 2023 | 43.56% |
| Jun 30, 2023 | 7.73% |
| Mar 31, 2023 | -64.41% |
| Dec 31, 2022 | -74.01% |
| Sep 30, 2022 | -15.30% |
| Jun 30, 2022 | -26.28% |
| Mar 31, 2022 | -2.88% |
| Dec 31, 2021 | 401.34% |
| Sep 30, 2021 | 157.95% |